產(chǎn)品編號(hào) | 圖片 | 產(chǎn)品描述 | 分子式 | 加入購(gòu)物車 | |
---|---|---|---|---|---|
PS 48,98% | C17H15ClO2 | ||||
|
|||||
Zotarolimus,98% | C52H79N5O12 | ||||
|
|||||
PI3Kδ-IN-2,98% | C28H37FN6O5S | ||||
|
|||||
MHY-1685,98% | C11H8N2O4 | ||||
|
|||||
Tenalisib,98% | C23H18FN5O2 | ||||
|
|||||
GNE-493,98% | C17H20N6O2S | ||||
|
|||||
ElteN378,98% | C23H26N2O3 | ||||
|
|||||
GSK-3β inhibitor 1,98% | C14H10N2O | ||||
|
|||||
WAY-352753,98% | C14H10ClN3OS | ||||
|
|||||
AS-041164,98% | C11H7NO4S | ||||
|
|||||
5H-Pyrazolo[3,4-b]quinolin-5-one, 1,4,6,7,8,9-hexahydro-3,7,7-trimethyl-4-(3-pyridinyl)-,98% | C18H20N4O | ||||
|
|||||
MOMIPP,98% | C18H16N2O2 | ||||
|
|||||
PI3Kδ-IN-3,98% | C28H24N6O3 | ||||
|
|||||
GSK-3β inhibitor 2,98% | C14H14N4O3S | ||||
|
|||||
GSK3β inhibitor II,98% | C14H10IN3OS | ||||
|